Dimensional Fund Advisors
VIR icon

Dimensional Fund Advisors’s Vir Biotechnology VIR Stock Holding History

Dimensional Fund Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$37.1M Buy
3,316,968
+197,547
+6% +$1.98M 0.01% 1737
2026
Q2 		$31.8M Buy
3,119,421
+539,743
+21% +$5.13M 0.01% 1825
2026
Q1 		$23.1M Buy
2,579,678
+43,401
+2% +$346K ﹤0.01% 1899
2025
Q4 		$15.3M Sell
2,536,277
-442,594
-15% -$2.64M ﹤0.01% 2111
2025
Q3 		$17M Sell
2,978,871
-29,084
-1% -$149K ﹤0.01% 2076
2025
Q2 		$15.2M Buy
3,007,955
+323,540
+12% +$1.73M ﹤0.01% 2088
2025
Q1 		$17.4M Buy
2,684,415
+768,950
+40% +$6.84M ﹤0.01% 2005
2024
Q4 		$14.1M Buy
1,915,465
+703,360
+58% +$5.55M ﹤0.01% 2163
2024
Q3 		$9.08M Buy
1,212,105
+574,619
+90% +$4.99M ﹤0.01% 2337
2024
Q2 		$5.67M Buy
637,486
+58,360
+10% +$560K ﹤0.01% 2455
2024
Q1 		$5.87M Buy
579,126
+110,807
+24% +$1.13M ﹤0.01% 2506
2023
Q4 		$4.71M Sell
468,319
-259,296
-36% -$2.37M ﹤0.01% 2576
2023
Q3 		$6.82M Sell
727,615
-295,124
-29% -$4.21M ﹤0.01% 2421
2023
Q2 		$25.1M Buy
1,022,739
+977,639
+2,168% +$24.6M 0.01% 1814
2023
Q1 		$1.05M Buy
+45,100
New +$1.15M ﹤0.01% 2893
2022
Q3 		$870K Sell
45,100
-72,279
-62% -$1.84M ﹤0.01% 2920
2022
Q2 		$2.99M Sell
117,379
-494,957
-81% -$11.6M ﹤0.01% 2615
2022
Q1 		$15.7M Buy
612,336
+291,785
+91% +$8.65M ﹤0.01% 2092
2021
Q4 		$13.4M Buy
320,551
+269,069
+523% +$10.5M ﹤0.01% 2189
2021
Q3 		$2.24M Buy
51,482
+13,793
+37% +$597K ﹤0.01% 2823
2021
Q2 		$1.78M Sell
37,689
-10,381
-22% -$472K ﹤0.01% 2896
2021
Q1 		$2.46M Buy
48,070
+38,200
+387% +$2.06M ﹤0.01% 2799
2020
Q4 		$264K Buy
9,870
+274
+3% +$8.91K ﹤0.01% 3190
2020
Q3 		$329K Buy
+9,596
New +$413K ﹤0.01% 3137

Other funds holding VIR

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Dimensional Fund Advisors's VIR Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Vir Biotechnology (VIR) stake by 6.3% in Q3 2026, buying an estimated $1.98M and bringing the position to 3,316,968 shares worth $37.1M. The position accounts for 0.01% of the portfolio, ranked #1737.

Dimensional Fund Advisors first reported a position in VIR in Q3 2020 and has held it in 24 quarters since. 135 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • Dimensional Fund Advisors held 3,316,968 shares of Vir Biotechnology worth $37.1M as of Q3 2026.
  • Dimensional Fund Advisors bought 197,547 Vir Biotechnology shares in Q3 2026, an estimated $1.98M.
  • Vir Biotechnology made up 0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #1737 holding.
  • Dimensional Fund Advisors first reported a position in Vir Biotechnology in Q3 2020 and has held it in 24 quarters since.
  • 135 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.